These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8938911)

  • 1. Placebo washout in trials of antipsychotic drugs.
    Volavka J; Cooper TB; Laska EM; Meisner M
    Schizophr Bull; 1996; 22(4):567-76. PubMed ID: 8938911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Untreated psychosis and long-term outcome in schizophrenia.
    Waddington JL; Scully PJ
    Schizophr Bull; 1998; 24(1):34-5. PubMed ID: 9502545
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
    Alphs L; Panagides J; Lancaster S
    Psychopharmacol Bull; 2007; 40(2):41-53. PubMed ID: 17514185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch or stay?
    Davis JM; Marder SR; Tamminga CA
    Am J Psychiatry; 2006 Dec; 163(12):2032-3. PubMed ID: 17151147
    [No Abstract]   [Full Text] [Related]  

  • 10. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
    Kemp AS; Schooler NR; Kalali AH; Alphs L; Anand R; Awad G; Davidson M; Dubé S; Ereshefsky L; Gharabawi G; Leon AC; Lepine JP; Potkin SG; Vermeulen A
    Schizophr Bull; 2010 May; 36(3):504-9. PubMed ID: 18723840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
    Sharma RP; Dowd SM; Davis JM; Janicak PG
    Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 14. Treating prodromal episodes to prevent relapse in schizophrenia.
    Herz MI; Glazer W; Mirza M; Mostert M; Hafez H
    Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
    [No Abstract]   [Full Text] [Related]  

  • 15. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional antipsychotic medications for schizophrenia.
    Dixon LB; Lehman AF; Levine J
    Schizophr Bull; 1995; 21(4):567-77. PubMed ID: 8749885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotic recurrence after antipsychotic discontinuation.
    Zipursky RB
    Am J Psychiatry; 2002 Aug; 159(8):1441-2; author reply 1442. PubMed ID: 12153856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.